Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy and safety of a combination of miglitol, metformin and insulin aspart in the treatment of type 2 diabetes

Tingyu Ke¹, Guoliang Cheng², Liping Tan², Xiangming Zhou¹, Yuanyuan Miao¹, Shigang Du¹, Jia Wang¹, Yi Pan¹, Jingjie Bi², Lin Zhao², Yunxia Zhi², Ling Zhao¹

¹Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101; ²National Engineering and Technology Research Centre of Chirality Pharmaceutical, Linyi, Shandong 276000, PR China.

For correspondence:- Ling Zhao Email: qeuer0@163.com Tel:+8613888173606

Accepted: 23 September 2021 Published: 31 October 2021

Citation: Ke T, Cheng G, Tan L, Zhou X, Miao Y, Du S, et al. Efficacy and safety of a combination of miglitol, metformin and insulin aspart in the treatment of type 2 diabetes. Trop J Pharm Res 2021; 20(10):2171-2177 doi: 10.4314/tjpr.v20i10.22

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the clinical effect of combining insulin aspart with different drugs in the treatment of type 2 diabetes mellitus (T2DM).

Methods: Two hundred and thirty-seven T2DM patients admitted to the Endocrinology Department of the Second Affiliated Hospital of Kunming Medical University from March to September 2018 were selected as subjects in this study. Miglitol and metformin were used in combination with insulin aspart in the treatment of T2DM. In addition, data on the effectiveness and safety of different treatment options, such as patient’s weight, waist circumference, blood glucose indicators, indices of heart, liver and kidney functions, and incidence of complications were recorded and compared between the two groups.

Results: The use of a combination of miglitol and insulin aspart produced an excellent hypoglycaemic effect, and it significantly reduced the incidence of sensory neuropathy in the eyes and distal limbs (p < 0.05). The use of combination of metformin and insulin aspart effectively protected the heart and kidney, and prevented hypoglycaemia (p < 0.05).

Conclusion: These results suggest that treatment with a combination of miglitol and insulin aspart is suitable for patients with T2DM whose blood sugar levels are out of control, while combined treatment with metformin and insulin aspart is more suited for patients who desire to reduce blood sugar and blood lipids through weight loss, and patients with cardiac and renal insufficiency.

Keywords: Type 2 diabetes, Insulin aspart, Miglitol, Metformin, Cardiac and renal insufficiency